Essetifin SPA 的 Form 4 申報
Regenerx Biopharmaceuticals Inc（RGRX），2023/7/6 申報
- 申報編號
- 0001213900-23-055186
- 申報時間
- 2023/7/6 16:30 ET
- 交易日
- 2023/7/3
- 申報延遲
- 3 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 2 筆衍生性交易。交易後 3 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Essetifin SPACIK 0001092601 | 持股 10% 以上大股東 |
| Cavazza PaoloCIK 0001163608 | 持股 10% 以上大股東 |
| Aptafin S P ACIK 0001232942 | 其他：Member of 10% owner group |
| Cavazza FrancescaCIK 0001525742 | 持股 10% 以上大股東 |
| Cavazza SilviaCIK 0001525743 | 持股 10% 以上大股東 |
| Cavazza EnricoCIK 0001525744 | 持股 10% 以上大股東 |
| Cavazza Preta MartinaCIK 0001718557 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
這份申報沒有這一類的交易。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F7
On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the "2023 Agreement"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the "2023 Note") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the "2023 Warrant").
表 II 有 2 筆交易的價格引用這則附註。
- F8
The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion.
表 II 有 1 筆交易的價格引用這則附註。
- F9
The 2023 Warrant is exercisable into up to 3,750,000 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from January 3, 2024, the date that is six months after the date of purchase, through July 2, 2028, the fifth anniversary of such date.
表 II 有 1 筆交易的價格引用這則附註。